174
Participants
Start Date
August 25, 2020
Primary Completion Date
November 12, 2024
Study Completion Date
August 31, 2029
Ropeginterferon alfa-2b
Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg
Anagrelide
Anagrelide dosage: 0.5 mg per capsule, according to label and physician's judgement
National Taiwan University Hospital, Taipei
Mackay Memorial Hospital, Taipei
Shin Kong Wu Ho-Su Memorial Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Tri-Service General Hospital, Taipei
Taipei Municipal Wan Fang Hospital, Taipei
Far Eastern Memorial Hospital, New Taipei City
Daegu Catholic University Hospital, Daegu
Linkou Chang Gung Memorial Hospital, Taoyuan
China Medical University Hospital, Taichung
Chia-Yi Christian Hospital, Chiayi City
Chiayi Chang Gung Memorial Hospital, Chiayi City
Washington University School of Medicine - Division of Oncology, St Louis
National Cheng Kung University Hospital, Tainan City
Tainan Municipal An-Nan Hospital, Tainan City
Chi Mei Medical Center, Tainan City
Chi-Mei Hospital - Liouying Branch, Tainan City
MD Anderson Cancer Center, Houston
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Kaohsiung Veterans General Hospital, Kaohsiung City
E-Da Cancer Hospital, Kaohsiung City
E-Da Hospital, Kaohsiung City
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
University of Utah, Salt Lake City
Hualien Tzu Chi Hospital, Hualien City
National University Hospital, Singapore
Singapore General Hospital, Singapore
The Second Hospital of Tianjin Medical University, Tianjin
St. Paul's Hospital, Vancouver
Princess Margaret Hospital, Toronto
Jewish General Hospital, Montreal
Peking Union Medical College Hospital, Beijing
Peking University People's Hospital, Beijing
The First Affiliated Hospital, Chongqing Medical University, Chongqing
NanFang Hospital of Southern Medical University, Guangzhou
Union Hospital Tongji Medical College Huazhong University of Science and Technolog, Wuhan
Zhongnan Hospital of Wuhan University, Wuhan
The First Affiliated Hospital of Soochow University, Suzhou
Shengjing Hospital of China Medical University, Shenyang
Shaanxi Provincial People's Hospital, Xi'an
Qilu Hospital of Shandong University, Jinan
Ruijin Hospital affiliated to Shanghai Jiao Tong University school of Medicine, Shanghai
West China Hospital, Sichuan University, Chengdu
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou
Queen Mary Hospital, Hong Kong
Ehime University Hospital, Tōon
Kitasato University Hospital, Sagamihara
Mie University Hospital, Tsu
University of Miyazaki Hospital, Miyazaki
Kansai Medical University Hospital, Hirakata
Kindai University Hospital, Sayama
Osaka University Hospital, Suita
Juntendo University Shizuoka Hospital, Izunokuni
Juntendo University Hospital, Bunkyo City
Nippon Medical School Hospital, Bunkyo City
NTT Medical Center Tokyo, Shinagawa City
Tokyo Medical University Hospital, Shinjuku
University of Yamanashi Hospital, Chūō
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
SoonChunHyang University Seoul Hospital, Seoul
Samsung Medical Center, Seoul
Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul
Korea University Guro Hospital, Seoul
Lead Sponsor
PharmaEssentia
INDUSTRY